News

McKesson Expands Operations with New Office in Downtown Evansville, Indiana

December 13, 2016

When Fully Staffed, the McKesson Indiana Regional Billing Office will Employ More than 100

EVANSVILLE, Indiana (December 13, 2016) — Evansville Mayor Lloyd Winnecke and McKesson announced that McKesson will expand its Revenue Cycle Services operations with the opening of a new office in Evansville, Indiana in early 2017. When fully staffed, the new McKesson Indiana Regional Billing Office will employ more than 100.

“I am excited that McKesson has chosen Evansville to locate this new office and create additional jobs for the City and the region,” said Mayor Winnecke. “This reinforces our focus and efforts of fostering job creation and business growth, and I expect McKesson’s industry leadership will serve as an invaluable contribution to the Indiana economy.”

Read More

US Oncology Research Annual Science Forum focuses on delivering the latest research opportunities to patients in the community setting

December 8, 2016

15th Annual Science Forum promotes clinical research education, innovation and collaboration

The Woodlands, Texas (December 8, 2016)US Oncology Research held its 15th Annual Science Forum earlier this fall. The annual meeting for all US Oncology Research affiliated investigators was held in Dallas and highlighted the importance of clinical trials as a treatment option for cancer patients.

“A clinical trial saved my life,” said Rhonda Jenkins, breast cancer survivor, clinical trial participant and patient of Texas Oncology, an affiliate of US Oncology Research.

Read More

Blood & Cancer Center Joins Florida Cancer Affiliates

December 1, 2016

Collaboration strengthens both practices, enhancing patient care, research opportunities and access to services throughout Northern Florida

Ocala, Fla. (December 1, 2016) — Florida Cancer Affiliates (FCA), a premier provider of advanced cancer care services in Florida, announced that Blood & Cancer Center has joined its practice. Anju Vasudevan, M.D., and Cecil Robertson, M.D., oncologists and hematologists with Blood & Cancer Center, will unite with Florida Cancer Affiliate’s group of physicians to provide comprehensive state-of-the-art cancer care in convenient, patient-friendly community settings. FCA is an affiliate of The US Oncology Network (The Network), one of the nation’s largest networks of integrated community-based oncology practices.

Read More

US Oncology Research Announces Schedule of Presentations at the 2016 American Society of Hematology Annual Meeting and Exposition

November 30, 2016

Sixteen presentations on clinical research conducted by top US Oncology Research affiliated investigators will take place at ASH 2016

The Woodlands, Texas (November 30, 2016) — More than 20 leading investigators affiliated with US Oncology Research participated in sixteen studies that will be presented at the 58th American Society of Hematology Annual Meeting and Exposition (ASH), a premier scientific event in malignant and non-malignant hematology, held December 3-6 in San Diego. Six oral and ten poster presentations co-authored by US Oncology Research affiliated investigators cover topics such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma, small lymphocytic leukemia, and mantle cell lymphoma.

Read More

Rocky Mountain Cancer Centers First In Region to Offer Newly Approved Gallium DOTATATE PET/CT for Neuroendocrine Tumors

November 15, 2016

Denver, Colo. (November 15, 2016) – Rocky Mountain Cancer Centers (RMCC), a practice in The US Oncology Network, is the first in the Rocky Mountain region, and one of only a handful of sites in the United States, to offer the newly approved Ga-68 DOTATATE PET/CT for patients with neuroendocrine tumors (NETs). The U.S. Food and Drug Administration (FDA) recently approved the test. Marketed under the name Netspot™, gallium 68 DOTATATE is a radioactive diagnostic agent used in positron emission tomography (PET) imaging. Because the gallium DOTATATE binds strongly to the receptors of neuroendocrine tumor cells, it effectively detects tumors and metastases, not seen on other standard scans, and reveals the locations of tumors.

Read More

Lancet Oncology Multi-Part Study on Oncology Drug Safety in the 21st Century Reveals the Need for New Approaches to Biosimilar and Generic Oncology Drugs

November 2, 2016

Much reform is needed before these new oncology drugs are safe, effective, affordable choices for U.S. patients

Read More

OHC Joins The US Oncology Network, Gaining Resources to Advance Quality Care and Operational Efficiency

November 1, 2016

Practice gains access to world-class treatments and enhances its cutting-edge research program

Cincinnati, Ohio (November 1, 2016) – OHC (Oncology Hematology Care), the premier provider of advanced treatments for cancer and blood disorders in the Greater Cincinnati area for more than 30 years, has joined The US Oncology Network, one of the nation’s largest associations of community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. By joining The Network, OHC enhances its ability to provide patients high-quality care as well as access to some of the most advanced cancer treatments available today, all delivered in convenient neighborhood locations close to the patient’s home. The practice also gains a wealth of resources, expertise, innovative technologies and business support services from The Network to help them succeed in transitioning to value-based healthcare.

Read More

Varian and McKesson Announce Strategic Agreement for Advanced Radiotherapy Equipment and Software

October 26, 2016

PALO ALTO, Calif. and The Woodlands, Texas (October 26, 2016) — Varian Medical Systems (NYSE: VAR) and McKesson today announced a strategic agreement for the deployment and servicing of Varian advanced radiotherapy equipment and software over a three-year period across The US Oncology Network affiliated sites of care. This multiyear agreement delivers significant value to oncology providers in The US Oncology Network, which now operates the largest system of radiotherapy facilities in the U.S. following the acquisition of Vantage Oncology earlier this year.

Read More

Compass Oncology breaks ground on multi-disciplinary cancer center

October 18, 2016

More than 80 healthcare employees will provide Westside residents with comprehensive care at new state-of-the-art facility

Tigard, Oregon (October 18, 2016) — The largest independent cancer practice in the Northwest has broken ground for a new multi-disciplinary center in Tigard, set to open May 2018. Construction at the site will begin spring 2017.

Compass Oncology, a practice in The US Oncology Network, one of the nation’s largest community-based cancer treatment and research networks, will build a 36,000 square-foot center near SW 72nd and SW Dartmouth in what is known as the Tigard Triangle.

Read More

The US Oncology Network Selects Myriad Genetics as Preferred Provider for Hereditary Cancer Testing

October 4, 2016

THE WOODLANDS, Texas and SALT LAKE CITY, Utah, October 4, 2016 – Myriad Genetics, Inc. (NASDAQ: MYGN) and The US Oncology Network (The Network) announced today that The Network has selected Myriad Genetic Laboratories as its preferred provider laboratory for hereditary cancer testing. The US Oncology Network is one of the nation’s largest networks of integrated, community-based, and independent physician practices dedicated to advancing high-quality, evidence-based cancer care. With more than 1,000 affiliated physicians in 19 states, providers in The Network treat over 800,000 patients every year.

Read More

Arizona Oncology implements advanced cervical imaging technology to assist with the early detection of cervical cancer

September 22, 2016

September 28th is National Women’s Health and Fitness Day and women are encouraged to take control of their health

Scottsdale, Ariz. (September 22, 2016) – Arizona Oncology, one of the largest medical groups in Arizona devoted to cancer care and a practice in The US Oncology Network, is the first in Arizona to utilize the latest technology and advancement in the early detection of cervical cancer and pre-cancers. The practice has implemented the DYSIS® Advanced Cervical Imaging System. This advanced digital colposcope, an instrument for examining the cervix, has computer-aided mapping technology and can enhance a doctor’s ability to diagnose and manage cervical neoplasia, precancerous cells, by detecting changes in a woman’s cervix after an abnormal Pap smear.

Read More

Arizona Oncology Adds Four Gynecologic Oncologists, Expanding World-Class Gynecologic Cancer Services throughout the Region

September 12, 2016

New physicians enhance access to specialized gynecologic care across the Valley

Read More

Missouri Cancer Associates Adds New Physician, Enhancing Access to Quality Care

August 9, 2016

Liana Makarian, M.D., brings leadership and quality improvement expertise to the practice, complementing MCA’s world-class care team

Columbia, Missouri (August 9, 2016) – Missouri Cancer Associates (MCA), the premier cancer treatment center in mid-Missouri and an affiliate of The US Oncology Network, has added another physician to the practice to meet growing demand for its services. Liana Makarian, M.D., a medical oncologist and hematologist, joined the practice in July, providing services from MCA’s Columbia and Kirksville treatment centers.

Read More

Arizona Oncology Breaks Ground for State-of-the-art Treatment Center in the East Valley

July 22, 2016

New facility at ASU Research Park will offer leading-edge cancer care to growing East Valley region

Tempe, Ariz., (July 22, 2016) - Arizona Oncology, one of the largest medical groups in Arizona devoted exclusively to cancer care and a practice in The US Oncology Network, held a groundbreaking ceremony today for its new state-of-the-art cancer treatment center in the East Valley. The new 21,000 square foot facility will be located at Arizona State University Research Park. Scheduled to open in April 2017, it will offer patients in the growing East Valley region convenient access to the very latest cancer treatment services and technologies available. The new treatment center is currently the only center in the East Valley that will provide medical, radiation and gynecologic oncology, and hematology services in one location. This provides patients a new treatment option for comprehensive advanced cancer care and supportive services.

Read More

Arizona Oncology Breaks Ground for State-of-the-art Treatment Center in the East Valley

July 22, 2016

New facility at ASU Research Park will offer leading-edge cancer care to growing East Valley region

Tempe, Ariz., (July 22, 2016) - Arizona Oncology, one of the largest medical groups in Arizona devoted exclusively to cancer care and a practice in The US Oncology Network, held a groundbreaking ceremony today for its new state-of-the-art cancer treatment center in the East Valley. The new 21,000 square foot facility will be located at Arizona State University Research Park. Scheduled to open in April 2017, it will offer patients in the growing East Valley region convenient access to the very latest cancer treatment services and technologies available. The new treatment center is currently the only center in the East Valley that will provide medical, radiation and gynecologic oncology, and hematology services in one location. This provides patients a new treatment option for comprehensive advanced cancer care and supportive services.

Read More

SpaceOAR® hydrogel is now available for prostate cancer patients being treated at Arizona Oncology

July 21, 2016

Tucson, Arizona (July 21, 2016) - Arizona Oncology, a practice in The US Oncology Network, is helping to pioneer a new tool proven to protect prostate cancer patients from the negative effects of radiation therapy. SpaceOAR hydrogel is the first FDA-cleared spacing device to protect the rectum in men undergoing radiation therapy for prostate cancer.

SpaceOAR hydrogel is a temporary injectable gel that protects the rectum in men undergoing radiation therapy for prostate cancer, decreasing the likelihood of side effects. It is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer, creating space to protect the rectum from radiation exposure. Arizona Oncology is the first treatment center in Southern Arizona to adopt the advanced technology.

Read More

Virginia Cancer Specialists First in the World to Enroll Patient in Cutting-Edge Lung Cancer Clinical Trial

July 14, 2016

Practice leads the way in bringing promising potential new therapy to patients with ALK-positive non-small cell lung cancer

Fairfax, Va. (July 14, 2016) Virginia Cancer Specialists (VCS), Virginia’s premier cancer care center with more than 40 years of providing service to patients battling cancer and blood diseases, is the first in the world to enroll a patient in a new advanced lung cancer clinical trial that may hold promise for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (ALK+ NSCLC). The randomized Phase III clinical trial focuses on brigatinib, an investigational anaplastic lymphoma kinase (ALK) inhibitor from ARIAD Pharmaceuticals, Inc. The trial is designed to assess the efficacy of the drug candidate in a head-to-head comparison with the current recommended therapy, crizotinib, evaluating progression free survival.

Read More

Virginia Cancer Specialists Receives Clinical Trials Research Award

July 12, 2016

Practice recognized for providing high-quality clinical trials in a community setting

Fairfax, Va. (July 12, 2016) Virginia Cancer Specialists (VCS), Northern Virginia’s premier cancer care center with more than 40 years of service to patients battling cancer and blood diseases, announced it is one of only three community oncology practices in the country recognized this year by the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) for its commitment to providing high-quality clinical trials to patients. As a recipient of the Conquer Cancer Foundation of ASCO Clinical Trials Participation Award, the VCS Research Institute is being honored for its contribution to the improvement of cancer care through clinical research in a community-based setting.

Read More

The US Oncology Network Announces Affiliated Practices Chosen To Participate In Oncology Care Model (OCM)

June 30, 2016

The Network will support practices with an innovative program to automate and simplify the OCM

The Woodlands, Texas (June 30, 2016)The US Oncology Network, supported by McKesson Specialty Health, announced today that 12 of its affiliated oncology practices have accepted the invitation to participate in the Centers for Medicare & Medicaid Services (CMS) Oncology Care Model (OCM). The OCM is a new, voluntary payment initiative introduced by CMS’ Innovation Center designed to support the transition to value-based care by advancing better care, smarter spending and healthier people. To help oncology practices successfully participate in the OCM and other value-based payment models, The US Oncology Network has developed a comprehensive program with innovative tools and resources.

Read More

The US Oncology Network Holds Intensive Boot Camp to Prepare Oncology Practices for July Launch of Oncology Care Model (OCM)

June 8, 2016

Training program provides OCM tools, technology and experience, preparing practice teams for July 1st go-live

The Woodlands, Texas (June 8, 2016) — Key personnel from practices within The US Oncology Network that were selected to participate in the Center for Medicare and Medicaid Innovation’s (CMMI) Oncology Care Model (OCM) gathered last month in The Woodlands, Texas, for a special OCM boot camp. The intensive two-day training program, attended by physicians, administrators and clinical staff, was designed to deliver expertise and share ideas for success from The US Oncology Network leadership and practice teams as they implement changes for the OCM July 1st go-live. The training seminar was a collaborative effort of The US Oncology Network and McKesson Specialty Health.

Read More

Pages